Pharmacokinetic and Pharmacodynamic Study of Golimumab in Ulcerative Colitis (UC) Patients With Secondary Loss of Response (LOR) to Maintenance Therapy Followed by Dose Optimization
Phase of Trial: Phase II
Latest Information Update: 31 Jan 2018
At a glance
- Drugs Golimumab (Primary)
- Indications Ulcerative colitis
- Focus Pharmacokinetics; Therapeutic Use
- 26 Jan 2018 Status changed from not yet recruiting to recruiting.
- 27 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 1 Dec 2017.
- 12 Jun 2017 New trial record